Comparative Pharmacology
Head-to-head clinical analysis: LASIX versus URESE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LASIX versus URESE.
LASIX vs URESE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Furosemide inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, reducing sodium, chloride, and water reabsorption and increasing urinary output.
Urease inhibitor; reduces bacterial conversion of urea to ammonia, lowering urine pH and ammonia concentration.
20-80 mg IV or PO once or twice daily; maximum 600 mg/day IV or PO.
Oral: 20 mg once daily. May increase to 40 mg once daily if needed after 4 weeks. Maximum: 40 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2 hours. In renal impairment (CrCl <20 mL/min), half-life may prolong to up to 2-4 hours; in end-stage renal disease or heart failure, may exceed 4 hours.
4-6 hours; prolonged in renal impairment (up to 12-15 hours in anuria).
Primarily renal excretion (50-80% as unchanged drug) via glomerular filtration and proximal tubular secretion; minor fecal elimination (<5%).
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other.
Category C
Category C
Loop Diuretic
Loop Diuretic